Month: January 2025

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights of this year’s conference were seven groundbreaking studies from Dr. Xiaowen Tang’s team at The First Affiliated Hospital of Soochow University. These included two oral presentations (O270, O683) and five poster presentations (P3384, P3493, P4197, P4284, P4836). Covering key areas such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), CAR-T cell therapy, and hematopoietic stem cell transplantation (HSCT), the research showcased the team's innovative contributions to hematology. Hematology Frontier interviewed Professor Tang on-site to explore the clinical significance of the two oral presentations, injecting new vitality into the advancement of hematology.

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights was a poster presentation (P4196) by Dr. Ying Wang from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study explored the efficacy and safety of CD19 CAR-T therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), demonstrating its potential to improve remission and survival rates. Hematology Frontier interviewed Professor Wang to analyze the study's key findings and the future prospects of CD19 CAR-T therapy.

Despite significant advancements in the treatment of multiple myeloma (MM) in recent years, particularly with the advent of innovative therapies, the prognosis for certain high-risk patient groups remains suboptimal. This is especially true for newly diagnosed multiple myeloma (NDMM) patients with renal impairment. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7–10, Wen Gao, Professor of Hematology at Beijing Chaoyang Hospital, presented findings from a study on the efficacy of the SPVD quadruple therapy as a first-line treatment for NDMM patients with renal impairment. The research offers a novel and promising solution to a pressing clinical challenge. Hematology Frontier invited Dr. Wen Gao to provide an in-depth analysis of this study and its significant implications for clinical practice.

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest and most comprehensive international conference in hematology, successfully took place from December 7 to 10, 2024, in San Diego, USA. This annual event attracts numerous hematology experts and scholars worldwide to exchange ideas and discuss significant breakthroughs in the field. During this year's ASH conference, the Chinese American Hematologist and Oncologist Network (CAHON) held its 2024 Winter Symposium. Experts shared insights, reviewed past accomplishments, and presented cutting-edge advancements in areas ranging from basic research to clinical applications. The event not only fostered academic exchanges and knowledge sharing but also played a pivotal role in advancing the diagnosis and treatment of related diseases while promoting global professional collaboration.

The 66th Annual Meeting of the American Society of Hematology (ASH) successfully concluded in San Diego, USA, from December 7–10, 2024. As the largest and most comprehensive international academic conference in the field of hematology, it attracts global experts and scholars each year to discuss and exchange views on the latest research advancements. During this year’s ASH meeting, the Chinese American Hematologist and Oncologist Network (CAHON) successfully held its Winter Symposium. Hematology frontier invited Dr. JingZhou Hou, CAHON President and a professor at the University of Pittsburgh Medical Center, to share insights on CAHON’s founding mission, highlights from this Winter Symposium, and details of his three research studies (including one oral presentation and two posters) presented at ASH.

The 2024 American Society of Hematology (ASH) Annual Meeting took place in San Diego from December 7 to 10, attracting the global hematology community's attention. As one of the most prestigious international events in the field, this conference has drawn keen interest from researchers and clinicians worldwide, including those in China. To provide timely updates on the most significant daily highlights, Oncology Frontier – Hematology Frontier launched the special column ASH Daily News Highlights. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the column features daily expert interviews, offering firsthand insights into the conference. We were honored to connect with Dr. Huiqiang Huang from the Lymphoma Center of Sun Yat-sen University Cancer Hospital to discuss the latest research in lymphoma presented at the conference.